Sichuan Kelun Pharmaceutical
Logotype for Sichuan Kelun Pharmaceutical Co Ltd

Sichuan Kelun Pharmaceutical (002422) investor relations material

Sichuan Kelun Pharmaceutical Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sichuan Kelun Pharmaceutical Co Ltd
Q3 2026 earnings summary28 Oct, 2026

Executive summary

  • Q3 revenue was ¥4.274bn, up 1.93% YoY; net income attributable to shareholders was ¥339.3m, up 69.60%.

  • 9M revenue was ¥13.113bn, down 1.24% YoY; attributable net income rose 22.18% to ¥1.467bn, while adjusted attributable net income fell 7.48% to ¥1.061bn.

Financial highlights

  • 9M operating cash flow increased 62.46% YoY to ¥2.737bn, with settlement proceeds and higher bill discounting cited as drivers.

  • 9M non-operating income reached ¥711.1m versus ¥4.6m a year earlier, mainly reflecting settlement proceeds; income tax expense fell 49.40% to ¥204.5m, partly due to a subsidiary tax refund.

  • Total assets were ¥43.032bn at Sept. 30, up 8.03% from year-end; parent-attributable equity was ¥25.993bn, up 7.30%.

Key financial ratios and metrics

  • Basic and diluted EPS were ¥0.21 in Q3, up 75.00% YoY; 9M EPS was ¥0.92, up 22.67%.

  • Weighted average ROE was 1.32% for Q3, up 0.49 percentage points YoY, and 5.91% for 9M, up 0.73 percentage points.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Sichuan Kelun Pharmaceutical earnings date

Logotype for Sichuan Kelun Pharmaceutical Co Ltd
H2 20262 Apr, 2027
Sichuan Kelun Pharmaceutical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Sichuan Kelun Pharmaceutical earnings date

Logotype for Sichuan Kelun Pharmaceutical Co Ltd
H2 20262 Apr, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Sichuan Kelun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio includes intravenous (IV) solutions, antibiotics, oncology treatments, and other specialty drugs, serving hospitals, healthcare facilities, and pharmacies. Sichuan Kelun focuses on developing generic and innovative drugs to address various therapeutic areas, including infectious diseases, oncology, and chronic conditions. In addition to pharmaceuticals, the company is involved in biotechnology research to expand its product offerings. The company is headquartered in Chengdu, China, and its shares are listed on the Shenzhen Stock Exchange.